Ashley Robinson

Has 25 years’ of experience in capital markets and corporate strategy experience. Employed since 2024. Before joining BioInvent, he served as Managing Director at LifeSci Advisors, where he established an office in Boston, advising key clients in the healthcare sector. Prior roles have been healthcare product specialist and sector head at Guggenheim Securities, Managing Director and Senior Partner at Leerink Partners, Vice President of ECM at Lehman Brothers. Born 1977.

Shareholding: -

Conditional employee options: Option program 2025/2027: 7,000

/sites/bioinvent/files/20241126-Ashley-Robinson.jpg Senior Vice President Strategy & Finance Management Team Off

Ingunn Munch Lindvig

PhD in Biology from the University of Oslo. Employed since 2023. Experienced regulatory affairs leader who has worked across all stages of product development and has hands-on experience of the US and EU regulatory systems. Previously Vice President and Head of Regulatory Affairs at Circio, Head of Regulatory Affairs at Nordic Nanovector and also held senior regulatory positions at Photocure and Nycomed/ GE Healthcare. Born 1965.

Shareholding: -

Conditional employee options: Option program 2023/2025: 19,741, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000
 

/sites/bioinvent/files/370x370-AI-BACKGROUND-iml%20mai%202023_small.png Senior Vice President Regulatory Affairs Management Team Off http://twitter.com/ http://linkedin.com/

Sylvie Ryckebusch

PhD in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland, College Park. Consultant since 2020. 25 years of experience in business development, alliance management, and corporate strategy with extensive experience negotiating complex deals. Sylvie has served in senior positions at Serono, Merck KGaA, numerous biotechs, and Medicxi Ventures as well as McKinsey & Company and the Harvard Business School. Born 1965.

Shareholding: 22,870 (own and affiliated holdings)

Conditional Employee options: -

/sites/bioinvent/files/bioinvert/sylvie.png Chief Business Officer Management Team Off

Kristoffer Rudenholm Hansson

Master of Science in Chemical engineering. Employed since 2016 and is responsible for process development and production of antibodies for clinical studies. He has 25 years of experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held numerous positions within CMC Biologics A/S (now AGC Biologics), DAKO A/S and Symphogen A/S. Born 1974.

Shareholding: 22,303 (whereof 7,177 in endowment insurance)

Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000

/sites/bioinvent/files/bioinvert/investors/corporate-governance/management-team/krist.png Senior Vice President, Technical Operations Management Team Off

Andres McAllister

Doctor in Medicine and Surgery from the Universidad del Rosario (Bogotá) and holds a PhD from the Institut Pasteur/Université Paris 7. Employed since 2017. He has performed academic work at the Pasteur Institute and the University of California, San Francisco on cancer immunotherapy. Andres was previously Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/ Pierre Fabre. Born 1956.

Shareholding: 3,009

Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000

/sites/bioinvent/files/bioinvert/investors/corporate-governance/management-team/mcallister-andres.png Chief Medical Officer Management Team Off

Björn Frendéus

Doctor of Immunology. Employed since 2001. Frequent publisher in leading scientific immunology journals, and speaker and chair at international Immuno-oncology conferences. Inventor on more than 150 patents and patent applications. Visiting Professor at University of Southampton. Born 1973.

Shareholding: 23,089 (own and affiliated holdings)

Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000

/sites/bioinvent/files/bioinvert/investors/corporate-governance/management-team/frendous.png Chief Scientific Officer Management Team Off

Stefan Ericsson

MBA, Lund University. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. Previous experience from the Swedish Tax Agency and as auditor at PricewaterhouseCoopers. Born 1963.

Shareholding: 8,000

Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000

/sites/bioinvent/files/people/Bioinvent%C2%A9Nille-Leander-5132.jpg Chief Financial Officer Management Team Off

Martin Welschof

PhD (Dr.rer.nat.) in recombinant antibody technology. Employed since 2018. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology, Germany. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech (Nasdaq Copenhagen) and CEO of Opsona Therapeutics, Dublin, Ireland. Member of the Board of Anocca, APIM Therapeutics AS and Nextera AS. Born 1961.

Shareholding: 22,400

Conditional Employee Options: Option program 2023/2025: 48,000, Option program 2024/2026: 30,000, Option program 2025/2027: 14,000

/sites/bioinvent/files/bioinvert/investors/corporate-governance/management-team/welcom-martin.png Chief Executive Officer Management Team Off
Subscribe to Management Team